Aspen Pharmacare Holdings Limited · JSE:APN

Aspen Pharmacare — FY2013 Earnings Presentation

77 slides from Aspen Pharmacare's earnings presentation, Sep 19, 2013

  1. Slide 1: Annual Results 2013

    Annual Results 2013

  2. Slide 2: Financial Highlights

    Group Financial Results Financial Highlights Revenue +27% to R19.3 billion • From continuing operations Operating profit +28% to R5.0 billion • From continuing operations Normalised diluted headline EPS +31% to 836 cents • From continuing operations Cash generated from operating activities +37% to R

  3. Slide 3: Statement of Comprehensive Income

    Group Financial Results Statement of Comprehensive Income Year ended Year ended 30 June 2013 30 June 2012 % CONTINUING OPERATIONS R'million R'million change Revenue 19 308 15 256 +27% Cost of sales (10 077) (7 980) Gross profit 9 231 7 276 +27% Net operating expenses (3 932) (3 123) EBITA 5 299 4 15

  4. Slide 4: Comparative reconciliation of earnings per share

    Group Financial Results Comparative reconciliation of earnings per share Year ended Year ended % 30 June 2013 30 June 2012 change Cents Cents Basic earnings per share (EPS) 773.0 645.8 +20% Discontinued operations - (36.5) Basic EPS from continuing operations 773.0 609.3 +27% Impairments 15.0 40.4 H

  5. Slide 5: Segmental contribution

    Group Financial Results Segmental contribution Gross revenue by region Normalised EBITA* by region 100% 100% 90% 90% 80% 38% 35% 35% 80% 40% 48% 70% 55% 55% 70% 60% 60% 60% 50% 50% 37% 34% 37% 33% 40% 13% 23% 40% 6% 19% 30% 30% 3% 9% 4% 10% 10% 5% 6% 20% 10% 20% 31% 27% 10% 23% 19% 10% 21% 21% 15% 1

  6. Slide 6: Revenue by customer geography

    Group Financial Results Revenue by customer geography SA Pharma +20% SA Consumer +18% SSA +29% 2013 6 202 2013 1 175 2013 2 124 2012 5 162 2012 998 2012 1 652 2011 5 178 2011 1 119 2011 1 301 2010 4 491 2010 1 084 2010 910 - 2 000 4 000 6 000 8 000 - 500 1 000 1 500 2 000 - 500 1 000 1 500 2 000 2 5

  7. Slide 7: Group operating margin

    Group Financial Results Group operating margin 25 000 35.0% 20 775 20 000 30.0% 26.9% 27.2% 27.1% 27.0% 27.0% 26.4% Margin % R'million 16 356 15 000 25.0% 13 214 10 088 10 000 20.0% 8 441 4 683 5 000 15.0% - 10.0% 2008 2009 2010 2011 2012 2013 Gross revenue Group normalised EBITA margin * Normalised

  8. Slide 8: South African business review

    Group Financial Results South African business review  What we said last year?  How we performed? ◦ Return to growth Strong organic growth ◦ Pharma division well set Momentum continued ◦ Strong product pipeline Leader in products launched by value ◦ Legislative uncertainty No change ◦ Awarded larg

  9. Slide 9: Asia Pacific business review

    Group Financial Results Asia Pacific business review  What we said last year?  How we performed? ◦ Biggest contributor to revenue Biggest contributor to revenue ◦ Further price disclosure cuts Lost revenue and margin ◦ Gains from procurement network Supported margin percentage ◦ Rationalisation of

  10. Slide 10: International business review

    Group Financial Results International business review  What we said last year?  How we performed? ◦ Expansion of portfolio Pending acquisitions ◦ Expanded territorial presence Pending acquisitions ◦ Ongoing COGS reduction projects Improved margins  Performance highlights  Outlook Normalised EBIT

  11. Slide 11: Sub Saharan Africa business review

    Group Financial Results Sub Saharan Africa business review  What we said last year?  How we performed? ◦ New product launches 37 products launched ◦ Growth strategies Partially effective ◦ Political uncertainty Constrained performance in Kenya and Nigeria  Performance highlights  Outlook Normali

  12. Slide 12: Statement of Financial Position

    Group Financial Results Statement of Financial Position As at As at 30 June 2013 30 June 2012 ASSETS R'million R'million Non-current assets 29 645 21 287 Property, plant and equipment 4 343 3 807 Intangible assets 18 933 11 870 Goodwill 5 973 5 344 Other non-current assets 396 266 Current assets 9 7

  13. Slide 13: Operating cash flows

    Group Financial Results Operating cash flows Year ended Year ended 30 June 2013 30 June 2012 % R'million R'million change Cash operating profit 5 960 4 746 +26% Changes in working capital (590) (870) Cash generated from operations 5 370 3 876 +39% Net finance costs paid (585) (514) Tax paid (799) (4

  14. Slide 14: Investment in Property, Plant and Equipment

    Group Financial Results Investment in Property, Plant and Equipment 800 700 667 652 627 632 600 R'million 500 470 400 379 288 295 300 253 215 200 168 119 100 60 75 - 2007 2008 2009 2010 2011 2012 2013 Capital Expenditure Depreciation R3.7 billion invested over 7 years 14

  15. Slide 15: Borrowings and liquidity

    Group Financial Results Borrowings and liquidity Operating net cash flows v Utilisation of free cash flows and net borrowings net borrowings in FY 2013 12 000 11 058 100% 90% 1 312 10 000 Free cash flows* 80% 715 3 824 8 000 7 068 Net borrowings# 70% 505 6 348 R'million 60% 6 000 Other 4 039 50% 3 9

  16. Slide 16: Borrowings and liquidity

    Group Financial Results Borrowings and liquidity Capital composition Net borrowings balances as at 30 June 2013 100% 100% 90% 90% 1.3 24% 29% 33% 3.3 34% 80% 80% 52% 70% 70% International 2.2 60% 60% Asia Pacific 3.5 50% 50% South Africa 40% 40% 76% 71% 67% 66% 30% 30% 48% 3.6 20% 20% 4.3 10% 10% 0%

  17. Slide 17: Merck Transactions: API business

    Impending Acquisitions Merck Transactions API business  Effective 1 October 2013  Acquisition of Dutch Newco (“Aspen Oss”) for €36 million  Inventory approximately €300 million ◦ Approximately €200 million relates to continuing supply to Merck under a loan repayable after 10 years  Ten year supp

  18. Slide 18: Merck Transactions: Option for product portfolio

    Impending Acquisitions Merck Transactions Option for product portfolio  Expected effective date 1 January 2014  Branded portfolio comprising 11 molecules  USD248 million of revenue in 2012  High correlation with target growth territories of Latam, Asia, CE Europe, the CIS  Dilutory currency imp

  19. Slide 19: GSK Transaction

    Impending Acquisitions GSK Transaction  Binding, irrevocable offer submitted to GSK on 18 June 2013 ◦ GSK will respond to the offer subject to consultation with employees and the relevant works councils  Arixtra and Fraxiparine brands worldwide (excluding China, India & Pakistan) ◦ Injectable anti

  20. Slide 20: Infant Nutritionals Latin America

    Impending Acquisitions Infant Nutritionals Latin America  Former Wyeth brands (S26 and SMA), acquired by Pfizer and subsequently Nestlé  Nestlé prevented from taking ownership in certain territories under competition regulations  Licence rights ◦ 10 years ◦ Allows brand transition ◦ Further 10 ye

  21. Slide 21: Impending Acquisitions Funding

    Impending Acquisitions Funding  Impending transactions to be funded with bank debt  Taking opportunity to restructure substantial portion of existing debt  Process well progressed ◦ Phase 1 – syndication with relationship banks – completed ◦ Phase 2 – syndication with international banks – in pro

  22. Slide 22: Distribution to shareholders

    Group Financial Results Distribution to shareholders 180 157 157 160 140 120 105 100 Cents 80 70 70 62 60 40 20 0 0 - 2006 2007 2008 2009 2010 2011 2012 2013  Impending acceleration of gearing  On going strong cash flows  Maintenance of distribution  Dividend of 131 cents – STC credits passed on

  23. Slide 23: Distribution of institutional shareholders

    Investors Distribution of institutional shareholders 100% 90% 80% 70% 60% Europe Asia Pacific 50% Middle East 40% North America Southern Africa 30% 20% 10% 0% 2010 2011 2012 2013  Southern African institutional shareholders have increased from 44% in 2010 to 55% in 2013 23

  24. Slide 24: Introduction

    Group Introduction  This is Aspen’s 30th set of results ◦ Record of unbroken growth remains intact  In period from 0 to >R100bn many defining commercial achievements ◦ Acquisitions of − South African Druggists − Sigma − Global brands ◦ Establishment of global − Manufacturing platform in South Afri

  25. Slide 25: Group revenue for year ended June

    Group Group revenue for year ended June Revenue R’million FY 2013 FY 2012 % change South Africa 7 377 6 160 20% Asia Pacific 7 590 6 021 26% Sub Saharan Africa 2 082 1 652 26% International 3 726 2 523 48% Gross Sales 20 775 16 356 27% Less: IFRS Adjustments (1 467) (1 100) 33% Total 19 308 15 256 2

  26. Slide 26: Private Pharmaceutical Market

    South Africa Private Pharmaceutical Market Total Private market value as at June 2013 R28.10bn Other R1.53 bn (2012: R26.44bn) (R1.37 bn) Market growth rates: Generic R6.64 bn (R5.80 bn) • Total market 6.3% Ethical/Branded R12.38 bn (R12.21 bn) • Ethical/Branded 1.4% • Generic 14.5% • OTC 7.0% OTC R

  27. Slide 27: Private Market Generics – MAT Value Share

    South Africa Private Market Generics – MAT Value Share Generics market value as at June 2013 R6.64bn (2012: R5.80bn) Dr Reddy's Lab Other 2.47% 14.08% Mylan Sevier 2.55% 2.81% Pharmaplan 3.01% Daiichi Sankyo Aspen 3.46% 33.30% Sanofi 5.28% Novartis 7.86% Adcock Ingram 8.73% Cipla Medpro 16.45% Sourc

  28. Slide 28: South African Market

    South Africa South African Market Private Pharmaceutical Market  Value of Pharma market dominated by branded/patented products ◦ Growth muted  Volumes and growth in generic sector  5.8% SEP increase implemented in March ◦ Price increase not sufficient to cover − Exchange rate − CPI OTC Market  S

  29. Slide 29: South African Market: Public Sector

    South Africa South African Market Public Sector  ARV tender award at R40 million per month ◦ Aspen won the largest share of 3-in-1 ARV tender (34%) − Capacity and reliability ◦ Supplying +/- R100 million per month − Mainly singles ◦ Off takes to increase from November ◦ Government expanding to 2.5

  30. Slide 30: Aspen South Africa

    South Africa Aspen South Africa Revenue R’million FY 2013 FY 2012 % change Pharma 6 202 5 162 20% Adjusted Pharma base 5 038 4 462 13% Tender ARV's and Intercompany 1 164 700 66% Consumer 1 175 998 18% Total 7 377 6 160 20% MAT Growth in Value as at June 2013 Market % Aspen % Position Total private

  31. Slide 31: Pharma Division Performance

    South Africa Pharma Division Performance  5 of the Top 7 Generics are Aspen products  Of Aspen’s Top 20 products in IMS: ◦ 17 growing faster than market ◦ Only 1 declining  Aspen has grown market share in both ◦ Generic and branded products  Generic market shares may be at all time high  The br

  32. Slide 32: Aspen Total MAT value trends

    South Africa Aspen Total MAT value trends MAT Value Share Trend MAT Value Growth Trend - Top 5 12% 18% ASPEN 10% 16% ADCOCK INGRAM SANOFI 8% 14% PFIZER ASPEN 6% 12% NOVARTIS ADCOCK 4% INGRAM 10% CIPLA MEDPRO NOVARTIS 2% 8% JOHNSON & SANOFI JOHNSON 0% 6% MERCK & CO PFIZER ASTRAZENECA -2% 4% BAYER -4%

  33. Slide 33: Aspen Generics MAT value trends

    South Africa Aspen Generics MAT value trends MAT Value Share Trend MAT Value Growth Trend – Top 5 35% 60% ASPEN 30% CIPLA 50% MEDPRO ADCOCK INGRAM 25% 40% SANOFI NOVARTIS ASPEN 20% 30% SANOFI CIPLA DAIICHI MEDPRO 15% SANKYO 20% NOVARTIS PHARMAPLAN 10% 10% ADCOCK SERVIER INGRAM 5% MYLAN 0% DR REDDYS

  34. Slide 34: Aspen Branded MAT value trends

    South Africa Aspen Branded MAT value trends MAT Value Share Trend MAT Value Growth Trend – Top 5 12% 15% SANOFI ASPEN 10% 10% PFIZER ASPEN 8% ASTRAZENECA 5% SANOFI MERCK & CO PFIZER 6% 0% ROCHE MERCK & CO NOVARTIS 4% -5% ASTRAZENECA BAYER 2% JOHNSON & -10% JOHNSON NOVO NORDISK 0% -15% Source: IMS TP

  35. Slide 35: Consumer Division Performance

    South Africa Consumer Division Performance Revenue R’million FY 2013 FY 2012 % change Consumer Division 1 175 998 18%  Strong underlying growth in IMF ◦ Good growth from base products ◦ GSK OTC brands added to consumer/OTC performance  Aspen offering dominated by IMFs ◦ First in SA to launch ready

  36. Slide 36: South Africa Prospects

    South Africa Prospects  Aspen is South Africa’s leading  The results are here for all to see pharmaceutical company ◦ Ready conversion to trusted  Margin pressure generics ◦ SEP does not cover input costs ◦ Growing market shares in pharma ◦ Continuing volumes increases − Branded and Generic secto

  37. Slide 37: Prospects - New Launch Income

    South Africa Prospects - New Launch Income Value Generated during Jun 2013 MAT Period (New Launches < 24 months) ASPEN ADCOCK SANOFI PFIZER NOVARTIS CIPLA MEDPRO ASTRAZENECA JOHNSON & MERCK & CO INGRAM JOHNSON Source: IMS DATA JUNE 2013 South Africa’s best pipeline 37

  38. Slide 38: Organic growth – Performance of Top products

    South Africa Organic growth – Performance of Top 10 products Sustained organic compound annual growth rate from base products 38

  39. Slide 39: Aspen Asia Pacific - Geographic Revenue

    Asia Pacific Aspen Asia Pacific - Geographic Revenue Australia/NZ performance (by customer geography) Asia Pacific revenue split 8 000 7 131 (by customer geography) 7 000 +24% Revenue in R'million 100% 5 768 6 000 90% 5 000 80% 4 000 3 000 70% 2 000 60% 1 000 50% 0 FY 2012 FY 2013 40% 30% Asia perfo

  40. Slide 40: Australian Market – MAT as at June 2013

    Asia Pacific Australian Market – MAT as at June 2013 Market valued at AU$13.95bn  Decline from AU$14.2bn in July (2012: AU$14.18bn) Pfizer 2012 $1 048m Others 8% AZ ◦ Volumes flat $7 074m $1 011m 51% 7%  Price cuts have been steeper Novartis than anticipated $848m 6% ◦ Initial value erosion higher

  41. Slide 41: Australia - Leading Manufacturers by Scripts Written

    Asia Pacific Australia - Leading Manufacturers by Scripts Written Aspen Aspen: Others 20% 23% - Owned 16% - Distributed 4%  Aspen sells over 700 Sanofi products and 100 9% million packs annually Generic 13% Pfizer 8% Munipharma 2% BI AZ 3% 7% MSD 3% GSK Alphapharm (Mylan) 5% 7% Source: IMS AMI MAT

  42. Slide 42: Australia’s Largest Generic Company by Value – 16%

    Asia Pacific Australia’s Largest Generic Company by Value – 16% Aspen $240m  Major patent Others $388m 16% expirations, e.g. 26% Atorvastatin negated Alphapharm ◦ Excessive (Mylan) discontinuing $205m Ascent $42m 14% ◦ PBS cuts 3% Pfizer $61m 4% Sanofi Apotex $67m $164m 5% 11% Hospira $73m 5% Baxte

  43. Slide 43: Australia - Performance

    Asia Pacific Australia - Performance Revenue analysis (by customer geography) R’million FY 2013 FY 2012 % change Australia base 6 435 5 768 12% Acquisitions: 695 - GSK OTC brands 205 - GSK Classic brands 353 - Nutritionals 137 - Total Australia 7 130 5 768 24%  Base business continues to perform 

  44. Slide 44: Australia – Breathing new life into OTC brands

    Asia Pacific Australia – Breathing new life into OTC brands MAT Value of acquired OTC brands +7.0% Sales in AU$ Zantac Relief (Groc) Zantac Relief (Rx) Beconase Cartia MAT Jun 2012 MAT Jun 2013 Source: IMS COMBINED AUDIT AND NIELSEN SCAN DATA  OTC brands acquired in April 2012 grew +7.0%  Aspen ra

  45. Slide 45: Australia – Operating performance

    Asia Pacific Australia – Operating performance  Good margin performance in difficult market ◦ Margins impacted by distribution of Group acquisitions ◦ On-going synergies from improved procurement and COGS ◦ Needed to off-set price reductions  Acquisitions bolster performance, complement and divers

  46. Slide 46: Infant milk formula market in Australia

    Asia Pacific Infant milk formula market in Australia  Well developed/mature market  Market expected to grow from US$266 million in 2011 to US$359 million by 2016* ◦ Expected CAGR of 6.2%* between 2011-2016  Top 3 players account for the majority of the market >85% in value  Wide distribution thr

  47. Slide 47: Aspen Nutritionals in Australia

    Asia Pacific Aspen Nutritionals in Australia  Diversifies product portfolio  Widely recognised by professionals and consumers ◦ S26 GOLD is leading recommended IMF brand in Australia ◦ S26 is one of top 10 consumer brands on IMS  Strong brand, comprehensive product offering and competitively pric

  48. Slide 48: Aspen Nutritionals – Opportunity into Asia

    Asia Pacific Aspen Nutritionals – Opportunity into Asia  Aspen currently assessing Asian markets for potential growth ◦ Aspen cannot use S26 brand here  Aspen has presence in Hong Kong, Japan, Taiwan, Philippines and Malaysia ◦ Look to leverage this position  Chinese market value of IMF estimated

  49. Slide 49: Asia - Performance

    Asia Pacific Asia - Performance Revenue R’million FY 2013 FY 2012 % change Asia base 446 321 39% GSK OTC brands 121 - Total 567 321 77% Revenue of R567m Thailand Rest of Asia 4% 13% Philippines 25% Indonesia 3% Hong Kong 12% Malaysia 12% Taiwan Japan 8% 23% Aspen Asia with the limited resource appli

  50. Slide 50: South East Asia

    Asia Pacific South East Asia June 2012 Dec 2012 June 2013 2014 • Philippines • Philippines • Philippines • Malaysia begins begins trading in ranked 34th by ranked 32nd by trading in July April 2012 with IMS (Ethicals) IMS (Ethicals) 2013 with 10 reps 100 reps • Malaysia • Taiwan business • Taiwan to

  51. Slide 51: Asia – Prospects

    Asia Pacific Asia – Prospects  Revenue more than doubled in first year of trading in Philippines  Malaysia the same for 2014  Philippines momentum to continue ◦ Growing product portfolio with domestic and global brands ◦ Product launches ◦ Licensing opportunities being explored ◦ Additional resou

  52. Slide 52: Sub Saharan Africa Performance

    Sub Saharan Africa Performance Gross Sales R2 081m (2012: R1 652m) Regional revenue growth rates Southern Africa 10% West 26% West Africa Africa 56% Southern 12% Africa East 30% Africa East Africa 34% SSA sales growth = 26% 52

  53. Slide 53: Sub Saharan Africa Performance and Prospects

    Sub Saharan Africa Performance and Prospects  Strong organic growth in all regions ◦ Despite political instability in key markets ◦ Diverse country base derisks region  Improved H2 performance ◦ Realisation of benefits of additional sales representatives ◦ EBITA growth +16% in H2 (H1: -10%)  Stro

  54. Slide 54: Latin America

    International Latin America Revenue R’million FY 2013 FY 2012 % change Brazil 817 575 42% Spanish Latam 750 448 67% Total 1 567 1 023 53% R’million FY 2013 FY 2012 % change Brazil Base 657 558 18% Novartis Rx brands 53 - GSK OTC brands 107 17 524% Total Brazil 817 575 42% Spanish Latam Base 578 424

  55. Slide 55: Aspen progress in Latin America

    International Aspen progress in Latin America Indexed sales in local currency 500% 450% 400% 350% Brazil* 300% Mexico Venezuela 250% 200% *initial years impacted by rationalisation of tender lines 150% 100% 2010 2011 2012 2013 Explosive growth 55

  56. Slide 56: Aspen Brazil’s performance of acquired OTC brand

    International Aspen Brazil’s performance of acquired OTC brand Aspen’s commercial impact Milk of Magnesia unit sales 2 150 000 2 100 000 2 050 000 2 000 000 Units 1 950 000 1 900 000 1 850 000 1 800 000 1 750 000 1 700 000 Pre Aspen Post Aspen Could have been higher – constrained by supply 56

  57. Slide 57: Aspen Nutritionals in Latin America

    International Aspen Nutritionals in Latin America  Exciting one off opportunity to enter branded market ◦ Forced divestment ◦ Rank between number 2 and number 4 in all traded markets  Good fit with pharma business ◦ Strong detail element ◦ Infrastructure to piggy back off ◦ Shared commercial teams

  58. Slide 58: Infant milk formula market in Latin America

    International Infant milk formula market in Latin America  Have presence in largest IMF market in the region – Mexico ◦ Also most other Latam markets 1 200 35.0% 988 30.0% 1 000 Market size in USD millions 25.0% 800 2012-2016 CAGR 697 20.0% 600 15.0% 400 10.0% 209 185 200 152 5.0% 46 40 33 - 0.0% M

  59. Slide 59: Aspen Nutritionals presence in Latin America

    International Aspen Nutritionals presence in Latin America  Consolidated IMF revenue in 2012*: USD187 million CARICAM MEXICO Revenue: $11m Revenue: $57m Total Ranking: #4 Total Ranking: #3 Commercial Commercial employees: 30 employees: 114 COLOMBIA ECUADOR Revenue: $20m Revenue: $15m Total Ranking:

  60. Slide 60: Infant milk formula manufacturing facility in Mexico

    International Infant milk formula manufacturing facility in Mexico Founded in: 1951 Location: Vallejo Industrial Park, Mexico City Building area: 29 645 m2  Production ~ 17 000 m2  Labs ~ 1 100m2  Warehouse ~ 8 000 m2 Number of employees: 247 2 Primacy processing Nutritional units Pharma/Consumer

  61. Slide 61: Latin America Highlights and Prospects

    International Latin America Highlights and Prospects  Region building off solid foundations  Business transformed from public sector tender business ◦ Now a branded pharmaceutical company  Sustained organic growth over last 4 years ◦ Commercial strategies working ◦ Sales >R1.5 billion ◦ With IMF

  62. Slide 62: Transforming Aspen

    Aspen Strategy Transforming Aspen Stated Strategic Objectives  Roll out Aspen presence across more geographies ◦ Acquire more products ◦ Critical mass − Convert from distribution model to an owned model ◦ Enhanced pipeline COFAL Fuerte® Brand Activation in Costa Rica − Differentiated, relevant and

  63. Slide 63: Transforming Aspen’s Geographic Sales Base

    Aspen Strategy Transforming Aspen’s Geographic Sales Base  Currently - 3 segments ◦ South Africa and Sub Saharan Africa ◦ Australia ◦ Rest of the World  By end of calendar year 2014 Aspen ◦ South Africa less than 25% of total sales ◦ Australia less than 25% of total sales ◦ Latam and Asia combined

  64. Slide 64: Transformation of Aspen’s Representative Base

    Aspen Strategy Transformation of Aspen’s Representative Base  In addition to the territory expansion across Asia, Latam and Sub Saharan Africa  Territories below should also have Aspen representation Western Europe CE Europe and CIS MENA France Russia Turkey Germany Poland Saudi Arabia Italy Czech

  65. Slide 65: Transformation of Aspen’s Capabilities

    Aspen Strategy Transformation of Aspen’s Capabilities  Access to niche APIs ◦ Tons to kgs ◦ Limited competitors/complex processes  Pipeline enhancement ◦ Pipeline developed from niche APIs ◦ Peptides, Biochemicals, Steroids and Hormonals API  Skills base acquired - APIs facilities ◦ Skilled perso

  66. Slide 66: Merck Transaction - Introduction

    Transaction overview Merck Transaction - Introduction  API manufacturing business in the Netherlands - October 2013 ◦ API stock on hand  Finish Dosage Form portfolio of eleven molecules - January 2014 ◦ Broad therapeutic range ◦ Mostly utilising acquired APIs  The IP related to Arixtra that gives

  67. Slide 67: Merck Transaction - Introduction

    Transaction overview Merck Transaction - Introduction  Biochemicals ◦ Biologicals with chemical extraction − Mucosa stomach lining of pigs − Urine from pregnant women/mares  Heparin – barriers high ◦ Traceability/deaths ◦ Swine flu ◦ Global share of just under 10%  Portfolio of niche APIs ◦ Devel

  68. Slide 68: Merck Transaction – The Products

    Transaction overview Merck Transaction – The Products  Aspen acquire a portfolio of products ◦ Limited/no molecular equivalents ◦ High margins/broad geography − Disproportionally higher in Latam and Asia ◦ Respond positively to promotional activity − Particularly Emerging Markets − Latam to be the

  69. Slide 69: GSK Transaction - Introduction

    Transaction overview GSK Transaction - Introduction  A sterile manufacturing plant, and stock on hand, in France ◦ May 2014  The acquisition of two finished dose form anti-coagulant products (Arixtra and Fraxiparine), both injectables ◦ January 2014  Sales approximately $500m ◦ Equal split  Frax

  70. Slide 70: GSK Transaction - Introduction

    Transaction overview GSK Transaction - Introduction  Opportunity ◦ Demand for anticoagulants expected to double globally next 5 years − Increase of lifestyle diseases − Ageing population globally − Greater healthcare access specifically in the emerging market Emerging market opportunity Current Ant

  71. Slide 71: GSK Transaction - Fraxiparine

    Transaction overview GSK Transaction - Fraxiparine  Fraxiparine is a biological ◦ Resilient to competition ◦ Biosimilars hard expensive to register ◦ None have been lodged and no competition anticipated over next 3 years  Turnover is stable ◦ Strong in Central/Eastern Europe and the CIS ◦ Potentia

  72. Slide 72: GSK Transaction - Arixtra

    Transaction overview GSK Transaction - Arixtra  Complex process ◦ Patent expired many years ago ◦ Just one competitor ◦ API was developed and manufactured in Oss  Margins high - generic threat ◦ Authorised generic strategy retained majority of USA market ◦ Strategy to defend Europe ◦ Emerging mark

  73. Slide 73: Synergies

    Transaction overview Synergies  Sales and Marketing staff ◦ Over 400 transferring employees ◦ Most are from the CIS and Central/Eastern Europe ◦ Enhances our global representation ◦ Specialist representatives − Contracts and appointments in place ◦ Orgaran fits in their promotional basket  Arixtra

  74. Slide 74: Strategic contribution from Operations

    Operations Strategic contribution from Operations  Our manufacturing and supply chain have been a key enabler in realising commercial deal closure  High potency suite ◦ Reduction in conversion, COGS more than halved  Oral solid dosage ◦ First Sigma volumes absorbed ◦ Only local manufacturer of 3-

  75. Slide 75: Summary and Prospects

    Summary and Prospects  Brilliant financial results ◦ All key financial indicators ◦ Strong cash flow ◦ Every region performing ◦ Operational excellence supporting performance  South Africa and Australia base businesses performing ◦ Financial plus cash flow  Global footprint increased ↑ Latam and

  76. Slide 76: Glossary

    Glossary Acronym Meaning Acronym Meaning API Active pharmaceutical ingredient IMS IMS Health, an independent provider of healthcare information and other services ARV Antiretroviral drug IP Intellectual property AUD or AU$ Australian Dollar Latam Latin America CAGR Compound annual growth rate MAT Mo

  77. Slide 77: Disclaimer

    Disclaimer Cautionary regarding forward-looking statements This presentation has been prepared by Aspen Pharmacare Holdings Limited based on information available to it as at the date of the presentation. This presentation may contain prospects, projections, future plans and expectations, strategy a

Aspen Pharmacare Holdings — FY2013 Earnings Presentation on 6ix